Log in

OTCMKTS:KHTRF - Knight Therapeutics Stock Price, Forecast & News

+0.03 (+0.52 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
Now: $5.77
50-Day Range
MA: $6.04
52-Week Range
Now: $5.77
Volume6,423 shs
Average Volume4,503 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; and TX-004HR for moderate-to-severe dyspareunia and TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. Further, the company develops TULSA-PRO, a medical device for prostate ablation. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Phone(514) 484-4483



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive KHTRF News and Ratings via Email

Sign-up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter.

Knight Therapeutics (OTCMKTS:KHTRF) Frequently Asked Questions

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

What price target have analysts set for KHTRF?

2 brokerages have issued 12 month price objectives for Knight Therapeutics' shares. Their forecasts range from $10.30 to $10.30. On average, they anticipate Knight Therapeutics' stock price to reach $10.30 in the next year. This suggests a possible upside of 78.6% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.

What is the consensus analysts' recommendation for Knight Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.

Has Knight Therapeutics been receiving favorable news coverage?

News headlines about KHTRF stock have trended somewhat positive on Saturday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Knight Therapeutics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Knight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Allena Pharmaceuticals (ALNA), Cray (CRAY), General Finance (GFN), NVIDIA (NVDA), Park City Group (PCYG), Ampliphi Biosciences (APHB), Viemed Healthcare (VMD), Arca Biopharma (ABIO), Arbutus Biopharma (ABUS) and AcelRx Pharmaceuticals (ACRX).

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the folowing people:
  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA, Founder, CEO & Director (Age 50)
  • Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
  • Mr. Michel Loustric, Pres of Knight Barbados
  • Ms. Jody Engel, Director of Bus. Devel.
  • Ms. Amal Khouri, VP of Bus. Devel.

How do I buy shares of Knight Therapeutics?

Shares of KHTRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $5.77.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is http://www.gud-knight.com/.

How can I contact Knight Therapeutics?

The company can be reached via phone at (514) 484-4483.

MarketBeat Community Rating for Knight Therapeutics (OTCMKTS KHTRF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe KHTRF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KHTRF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel